Sign in

    Carolina Ibanez-VentosoStifel, Nicolaus & Company, Incorporated

    Carolina Ibanez-Ventoso is an Associate Vice President and Equity Analyst at Stifel, Nicolaus & Company, specializing in equity research within the finance and consumer services sectors. Since joining Stifel in 2019, she has covered publicly traded companies, providing investment insights and analytical reports, though specific company names and detailed performance metrics are not publicly available. Ibanez-Ventoso began her analyst career at Janney Montgomery Scott LLC in 2015, progressed to Citigroup Global Markets as a Senior Associate from 2018 to 2019, and then continued her career at Stifel. She holds a doctorate from the University of Glasgow, an MBA from Rutgers University-Newark, an undergraduate degree from the Autonomous University of Barcelona, and is FINRA registered as a broker.

    Carolina Ibanez-Ventoso's questions to Allogene Therapeutics Inc (ALLO) leadership

    Carolina Ibanez-Ventoso's questions to Allogene Therapeutics Inc (ALLO) leadership • Q4 2024

    Question

    Carolina Ibanez-Ventoso, on for Ben Burnett from Stifel, asked about the specific timing of the MRD conversion measurement for the mid-2025 interim analysis of the cema-cel trial.

    Answer

    Dr. Zachary Roberts, EVP of R&D and CMO, responded that the company has not disclosed the exact timing of the MRD measurement for the lymphodepletion decision, noting it is one of several factors that will be assessed.

    Ask Fintool Equity Research AI